Compare Eli Lilly And Co (LLY) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Marsh (MRSH) trades at $181.79, down slightly (-0.21%) on the day. The stock exhibits a bullish technical trend with strong moving average signals, while fundamentals are solid with consistent revenue growth to $26.98B in 2025 and a robust net income margin of 14.26%. Recent news highlights a 10% dividend increase to $0.99 per share and strategic partnerships expanding its advisory business. The company has beaten earnings estimates for the last three consecutive quarters.

The outlook for MRSH is positive, supported by earnings momentum and shareholder returns, though rising operating expenses and a premium valuation (P/E of 22.77) present near-term risks. Analyst consensus is a 'Hold' with a $203.75 price target, suggesting modest upside potential from current levels, but investor sentiment is tempered by cost pressures.